Identifying B and T cell epitopes and studying humoral, mucosal and cellular immune responses of peptides derived from V antigen of Yersinia pestis

Vaccine

Volumn 26, Issue 3, 2008, Pages 316-332

  Khan, Arif Azam ^a   Babu, Jaya Prakash ^a   Gupta, Geetanjali ^a   Rao, D N ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Competitive ELISA; Microsphere; V antigen

Indexed keywords

ASPARTYLASPARAGINYLGLUTAMINYLLEUCYLGLUTAMINYLASPARAGINYLGLYCYLISOLEUCYLLYSYLARGINYLVALYLLYSYLGLUTAMYLPHENYLALANYLLEUCINE; ASPARTYLISOLEUCYLGLUTAMYLLEUCYLLEUCYLLYSYLLYSYLISOLEUCYLLEUCYLALANYLGLYCYLGLYCYLPHENYLALANYLISOLEUCYLGLUTAMINYLLYSYLTYROSYLASPARTYLSERYLVALYLMETHIONYLGLUTAMINE; BACTERIAL VACCINE; GLUTAMINYLLEUCYLVALYLLYSYLASPARTYLLYSYLASPARAGINYLISOLEUCYLASPARTYLISOLEUCYLLYSYLTYROSYLASPARTYLPROLYLARGINYLLYSYLASPARTYLSERYLGLUTAMIC ACID VACCINE; GLUTAMYLSERYLSERYLPROLYLASPARAGINYLTHREONYLGLUTAMINYLTRYPTOPHANYLGLUTAMYLLEUCYLARGINYLALANYLPHENYLALANYLMETHIONYLALANINE; GLUTAMYLTYROSYLLYSYLISOLEUCYLLEUCYLGLUTAMYLLYSYLMETHIONYLPROLYLGLUTAMINYLTHREONYLTHREONYLISOLEUCYLGLUTAMINYLVALYLASPARTYLGLYCYLSERYLGLUTAMYLLYSYLLYSYLISOLEUCINE; GLYCYLSERYLGLUTAMYLASPARAGINYLLYSYLARGINYLTHREONYLGLYCYLALANYLLEUCYLGLYCYLASPARAGINYLLEUCYLLYSYLASPARAGINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; INTERLEUKIN 10; ISOLEUCYLSERYLISOLEUCYLLYSYLASPARTYLPROLYLARGINYLLYSYLASPARTYLSERYLGLUTAMYLVALYLPHENYLALANYLALANINE; LEUCYLTHREONYLALANYLGLUTAMYLLEUCYLLYSYLISOLEUCYLTYROSYLSERYLVALYLISOLEUCYLGLUTAMINYLALANYLGLUTAMYLISOLEUCYLASPARAGINYLLYSYLHISTIDYLLEUCINE; PEPTIDE; SECRETORY IMMUNOGLOBULIN; SERYLTYROSYLSERYLTYROSYLASPARAGINYLLYSYLASPARTYLASPARAGINYLASPARAGINYLGLUTAMYLLEUCYLSERYLHISTIDYLPHENYLALANYLALANINE; THREONYLTHREONYLCYSTEINYLSERYLASPARTYLLYSYLSERYLARGINYLPROLYLLEUCYLASPARAGINYLASPARTYLLEUCYLVALYLSERINE; UNCLASSIFIED DRUG; VALYLMETHIONYLHISTIDYLPHENYLALANYLSERYLLEUCYLTHREONYLALANYLASPARTYLARGINYLGLYCYLGLYCYLGLUTAMYLLEUCYLLYSYLISOLEUCYLTYROSYLSERYLVALYLISOLEUCYLGLUTAMINYLALANINE; VIRUS PROTEIN V;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; HUMORAL IMMUNITY; IMMUNE RESPONSE; LUNG LAVAGE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; T LYMPHOCYTE; TH1 CELL; TH2 CELL; YERSINIA PESTIS;

ANIMALS; ANIMALS, OUTBRED STRAINS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; FEMALE; IMMUNITY, MUCOSAL; IMMUNIZATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICROSPHERES; MODELS, MOLECULAR; PEPTIDES; PORE FORMING CYTOTOXIC PROTEINS; YERSINIA PESTIS;

EID: 37549001712     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.11.028     Document Type: Article

References (65)

1. Perry R.D., and Fetherston J.D. Yersinia pestis-etiologic agent of plague. Clin Microbiol Rev 10 1 (1997) 35-66
2. Gage K.L., and Kosoy M.Y. Natural history of plague: perspectives from more than a century of research. Annu Rev Entomol 50 (2005) 505-528
3. Inglesby T.V., Dennis D.T., Henderson D.A., Bartlett J.G., Ascher M.S., Eitzen E., et al. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 283 17 (2000) 2281-2290
4. Meyer K.F. Effectiveness of live or killed plague vaccines in man. Bull World Health Org 42 5 (1970) 653-666
5. Williamson E.D. Plague vaccine research and development. J Appl Microbiol 91 4 (2001) 606-608
6. Du Y., Rosqvist R., and Forsberg A. Role of fraction 1 antigen of Yersinia pestis in inhibition of phagocytosis. Infect Immun 70 3 (2002) 1453-1460
7. Andrews G.P., Heath D.G., Anderson Jr. G.W., Welkos S.L., and Friedlander A.M. Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge. Infect Immun 64 6 (1996) 2180-2187
8. 2+-response plasmid pCD1 of Yersinia pestis KIM5. Infect Immun 66 10 (1998) 4611-4623
9. Derewenda U., Mateja A., Devedjiev Y., Routzahn K.M., Evdokimov A.G., Derewenda Z.S., et al. The structure of Yersinia pestis V-antigen, an essential virulence factor and mediator of immunity against plague. Structure 12 2 (2004) 301-306
10. Holmstrom A., Olsson J., Cherepanov P., Maier E., Nordfelth R., Pettersson J., et al. LcrV is a channel size-determining component of the Yop effector translocon of Yersinia. Mol Microbiol 39 3 (2001) 620-632
11. Mueller C.A., Broz P., Muller S.A., Ringler P., Erne-Brand F., Sorg I., et al. The V-antigen of Yersinia forms a distinct structure at the tip of injectisome needles. Science 310 5748 (2005) 674-676
12. Mota L.J. Type III secretion gets an LcrV tip. Trends Microbiol 14 5 (2006) 197-200
13. Matson J.S., and Nilles M.L. Interaction of the Yersinia pestis type III regulatory proteins LcrG and LcrV occurs at a hydrophobic interface. BMC Microbiol 2 (2002) 16
14. Viboud G.I., and Bliska J.B. Yersinia outer proteins: role in modulation of host cell signaling responses and pathogenesis. Annu Rev Microbiol 59 (2005) 69-89
15. Marketon M.M., DePaolo R.W., DeBord K.L., Jabri B., and Schneewind O. Plague bacteria target immune cells during infection. Science 309 5741 (2005) 1739-1741
16. Nedialkov Y.A., Motin V.L., and Brubaker R.R. Resistance to lipopolysaccharide mediated by the Yersinia pestis V antigen-polyhistidine fusion peptide: amplification of interleukin-10. Infect Immun 65 4 (1997) 1196-1203
17. Overheim K.A., Depaolo R.W., Debord K.L., Morrin E.M., Anderson D.M., Green N.M., et al. LcrV plague vaccine with altered immunomodulatory properties. Infect Immun 73 8 (2005) 5152-5159
18. Nakajima R., Motin V.L., and Brubaker R.R. Suppression of cytokines in mice by protein A-V antigen fusion peptide and restoration of synthesis by active immunization. Infect Immun 63 8 (1995) 3021-3029
19. Brubaker R.R. Interleukin-10 and inhibition of innate immunity to Yersiniae: roles of Yops and LcrV (V antigen). Infect Immun 71 7 (2003) 3673-3681
20. Sing A., Rost D., Tvardovskaia N., Roggenkamp A., Wiedemann A., Kirschning C.J., et al. Yersinia V-antigen exploits toll-like receptor 2 and CD14 for interleukin 10-mediated immunosuppression. J Exp Med 196 8 (2002) 1017-1024
21. Sing A., Reithmeier-Rost D., Granfors K., Hill J., Roggenkamp A., and Heesemann J. A hypervariable N-terminal region of Yersinia LcrV determines Toll-like receptor 2-mediated IL-10 induction and mouse virulence. Proc Natl Acad Sci USA 102 44 (2005) 16049-16054
22. Sing A., Roggenkamp A., Geiger A.M., and Heesemann J. Yersinia enterocolitica evasion of the host innate immune response by V antigen-induced IL-10 production of macrophages is abrogated in IL-10-deficient mice. J Immunol 168 3 (2002) 1315-1321
23. Reithmeier-Rost D., Hill J., Elvin S.J., Williamson D., Dittmann S., Schmid A., et al. The weak interaction of LcrV and TLR2 does not contribute to the virulence of Yersinia pestis. Microbes Infect 9 8 (2007) 997-1002
24. Abramov V.M., Khlebnikov V.S., Vasiliev A.M., Kosarev I.V., Vasilenko R.N., Kulikova N.L., et al. Attachment of LcrV from Yersinia pestis at dual binding sites to human TLR-2 and human IFN-gamma receptor. J Proteome Res 6 6 (2007) 2222-2231
25. Pouliot K., Pan N., Wang S., Lu S., Lien E., and Goguen J.D. Evaluation of the role of LcrV-Toll-like receptor 2-mediated immunomodulation in the virulence of Yersinia pestis. Infect Immun 75 7 (2007) 3571-3580
26. Leary S.E., Williamson E.D., Griffin K.F., Russell P., Eley S.M., and Titball R.W. Active immunization with recombinant V antigen from Yersinia pestis protects mice against plague. Infect Immun 63 8 (1995) 2854-2858
27. Anderson Jr. G.W., Leary S.E., Williamson E.D., Titball R.W., Welkos S.L., Worsham P.L., et al. Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis. Infect Immun 64 11 (1996) 4580-4585
28. Palin A., Chattopadhyay A., Park S., Delmas G., Suresh R., Senina S., et al. An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge. Vaccine 25 4 (2007) 741-750
29. Chiuchiolo M.J., Boyer J.L., Krause A., Senina S., Hackett N.R., and Crystal R.G. Protective immunity against respiratory tract challenge with Yersinia pestis in mice immunized with an adenovirus-based vaccine vector expressing V antigen. J Infect Dis 194 9 (2006) 1249-1257
30. Sato K., Nakajima R., Hara F., Une T., and Osada Y. Preparation of monoclonal antibody to V antigen from Yersinia pestis. Contrib Microbiol Immunol 12 (1991) 225-229
31. Motin V.L., Nakajima R., Smirnov G.B., and Brubaker R.R. Passive immunity to Yersiniae mediated by anti-recombinant V antigen and protein A-V antigen fusion peptide. Infect Immun 62 10 (1994) 4192-4201
32. Roggenkamp A., Geiger A.M., Leitritz L., Kessler A., and Heesemann J. Passive immunity to infection with Yersinia spp. mediated by anti-recombinant V antigen is dependent on polymorphism of V antigen. Infect Immun 65 2 (1997) 446-451
33. Hill J., Leary S.E., Griffin K.F., Williamson E.D., and Titball R.W. Regions of Yersinia pestis V antigen that contribute to protection against plague identified by passive and active immunization. Infect Immun 65 11 (1997) 4476-4482
34. Philipovskiy A.V., Cowan C., Wulff-Strobel C.R., Burnett S.H., Kerschen E.J., Cohen D.A., et al. Antibody against V antigen prevents Yop-dependent growth of Yersinia pestis. Infect Immun 73 3 (2005) 1532-1542
35. Cowan C., Philipovskiy A.V., Wulff-Strobel C.R., Ye Z., and Straley S.C. Anti-LcrV antibody inhibits delivery of Yops by Yersinia pestis KIM5 by directly promoting phagocytosis. Infect Immun 73 9 (2005) 6127-6137
36. Hill J., Eyles J.E., Elvin S.J., Healey G.D., Lukaszewski R.A., and Titball R.W. Administration of antibody to the lung protects mice against pneumonic plague. Infect Immun 74 5 (2006) 3068-3070
37. Elvin S.J., Eyles J.E., Howard K.A., Ravichandran E., Somavarappu S., Alpar H.O., et al. Protection against bubonic and pneumonic plague with a single dose microencapsulated sub-unit vaccine. Vaccine 24 20 (2006) 4433-4439
38. Anderson Jr. G.W., Heath D.G., Bolt C.R., Welkos S.L., and Friedlander A.M. Short- and long-term efficacy of single-dose subunit vaccines against Yersinia pestis in mice. Am J Trop Med Hyg 58 6 (1998) 793-799
39. Titball R.W., and Williamson E.D. Vaccination against bubonic and pneumonic plague. Vaccine 19 30 (2001) 4175-4184
40. Heath D.G., Anderson Jr. G.W., Mauro J.M., Welkos S.L., Andrews G.P., Adamovicz J., et al. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine 16 11-12 (1998) 1131-1137
41. Hill J., Copse C., Leary S., Stagg A.J., Williamson E.D., and Titball R.W. Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis. Infect Immun 71 4 (2003) 2234-2238
42. Jones S.M., Griffin K.F., Hodgson I., and Williamson E.D. Protective efficacy of a fully recombinant plague vaccine in the guinea pig. Vaccine 21 25-26 (2003) 3912-3918
43. Glynn A., Roy C.J., Powell B.S., Adamovicz J.J., Freytag L.C., and Clements J.D. Protection against aerosolized Yersinia pestis challenge following homologous and heterologous prime-boost with recombinant plague antigens. Infect Immun 73 8 (2005) 5256-5261
44. Reed D.S., and Martinez M.J. Respiratory immunity is an important component of protection elicited by subunit vaccination against pneumonic plague. Vaccine 24 13 (2006) 2283-2289
45. Jones T., Adamovicz J.J., Cyr S.L., Bolt C.R., Bellerose N., Pitt L.M., et al. Intranasal Protollin/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection. Vaccine 24 10 (2006) 1625-1632
46. Santi L., Giritch A., Roy C.J., Marillonnet S., Klimyuk V., Gleba Y., et al. Protection conferred by recombinant Yersinia pestis antigens produced by a rapid and highly scalable plant expression system. Proc Natl Acad Sci USA 103 4 (2006) 861-866
47. Alvarez M.L., Pinyerd H.L., Crisantes J.D., Rigano M.M., Pinkhasov J., Walmsley A.M., et al. Plant-made subunit vaccine against pneumonic and bubonic plague is orally immunogenic in mice. Vaccine 24 14 (2006) 2477-2490
48. Mett V., Lyons J., Musiychuk K., Chichester J.A., Brasil T., Couch R., et al. A plant-produced plague vaccine candidate confers protection to monkeys. Vaccine 25 16 (2007) 3014-3017
49. Williamson E.D., Flick-Smith H.C., Lebutt C., Rowland C.A., Jones S.M., Waters E.L., et al. Human immune response to a plague vaccine comprising recombinant F1 and V antigens. Infect Immun 73 6 (2005) 3598-3608
50. Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine 25 30 (2007) 5467-5484
51. Williamson E.D., Eley S.M., Stagg A.J., Green M., Russell P., and Titball R.W. A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunized animals against pneumonic plague. Vaccine 15 10 (1997) 1079-1084
52. Tripathi V., Chitralekha K.T., Bakshi A.R., Tomar D., Deshmukh R.A., Baig M.A., et al. Inducing systemic and mucosal immune responses to B-T construct of F1 antigen of Yersinia pestis in microsphere delivery. Vaccine 24 16 (2006) 3279-3289
53. Sabhnani L., Manocha M., Tomar D., Shashikiran D., and Rao D.N. Yersinia pestis F1 antigen: a correlation between antibody titres and subclass distribution with differential avidity in different inbred mouse strains. Int Immunopharmacol 3 10-11 (2003) 1413-1418
54. Sabhnani L., and Rao D.N. Identification of immunodominant epitope of F1 antigen of Yersinia pestis. FEMS Immunol Med Microbiol 27 2 (2000) 155-162
55. Sabhnani L., Manocha M., Sridevi K., Shashikiran D., Rayanade R., and Rao D.N. Developing subunit immunogens using B and T cell epitopes and their constructs derived from the F1 antigen of Yersinia pestis using novel delivery vehicles. FEMS Immunol Med Microbiol 38 3 (2003) 215-229
56. Friguet B., Chaffotte A.F., Djavadi-Ohaniance L., and Goldberg M.E. Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J Immunol Methods 77 2 (1985) 305-319
57. Dong X.N., Qi Y., Ying J., Chen X., and Chen Y.H. Candidate peptide-vaccine induced potent protection against CSFV and identified a principal sequential neutralizing determinant on E2. Vaccine 24 4 (2006) 426-434
58. Liu G.J., Yang L.M., Wang J.H., Zhang G.H., Chen X.M., and Zheng Y.T. Immune responses to six synthetic peptides of capsid protein with sera from HIV-1 infected individuals. Cell Mol Immunol 2 4 (2005) 289-293
59. Torres D., and Espino A.M. Mapping of B-cell epitopes on a novel 11.5-kilodalton Fasciola hepatica-Schistosoma mansoni cross-reactive antigen belonging to a member of the F. hepatica saposin-like protein family. Infect Immun 74 8 (2006) 4932-4938
60. Williamson E.D., Vesey P.M., Gillhespy K.J., Eley S.M., Green M., and Titball R.W. An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model. Clin Exp Immunol 116 1 (1999) 107-114
61. Sundaram R., Lynch M.P., Rawale S.V., Sun Y., Kazanji M., and Kaumaya P.T. De novo design of peptide immunogens that mimic the coiled coil region of human T-cell leukemia virus type-1 glycoprotein 21 transmembrane subunit for induction of native protein reactive neutralizing antibodies. J Biol Chem 279 23 (2004) 24141-24151
62. Pullen J.K., Anderson Jr. G.W., Welkos S.L., and Friedlander A.M. Analysis of the Yersinia pestis V protein for the presence of linear antibody epitopes. Infect Immun 66 2 (1998) 521-527
63. Parent M.A., Berggren K.N., Mullarky I.K., Szaba F.M., Kummer L.W., Adamovicz J.J., et al. Yersinia pestis V protein epitopes recognized by CD4 T cells. Infect Immun 73 4 (2005) 2197-2204
64. Shim H.K., Musson J.A., Harper H.M., McNeill H.V., Walker N., Flick-Smith H., et al. Mechanisms of major histocompatibility complex class II-restricted processing and presentation of the V antigen of Yersinia pestis. Immunology 119 3 (2006) 385-392
65. Humphrey W., Dalke A., and Schulten K. VMD: visual molecular dynamics. J Mol Graph 14 1 (1996) 33-38 27-38